{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:03:13Z","timestamp":1768798993130,"version":"3.49.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Natural Science Foundation of Jiangxi","award":["20171BAB205057"],"award-info":[{"award-number":["20171BAB205057"]}]},{"name":"Research Project of the Jiangxi Health Committee","award":["20184023"],"award-info":[{"award-number":["20184023"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Locoregional recurrence of breast cancer is a challenging issue for clinicians. Treatment options for unresectable recurrent estrogen receptor positive (ER+) breast cancer in previously irradiated area are limited. Some studies showed concomitant fulvestrant with radiation therapy might increase radiosensitivity compared with radiation alone in vitro, no in vivo reports yet.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concern:<\/jats:title>\n            <jats:p>Here, we present a case report and make a narrative review of concomitant fulvestrant with radiation therapy for unresectable locoregional recurrent ER+ breast cancer. The patient was treated with modified radical mastectomy in 2015, adjuvant chemotherapy, radiotherapy, followed by exemestane until November 2018, relapsed in internal mammary lymph nodes with sternum involved.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>The final diagnosis was breast cancer internal mammary lymph nodes metastasis with sternum involved.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>After diagnosis was made, concurrent fulvestrant with reirradiation as a palliative treatment were proposed under multiple disciplinary team.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>There was a good clinical response, enabling curative chance with radiation therapy to a total dose of 60\u200aGy. Computed tomography scan revealed no evidence of residual tumor.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>As far as we know, this is the first report concerning concomitant fulvestrant with reirradiation for unresectable locoregional recurrent ER+ breast cancer. Since no severe adverse events were observed, this strategy could be a suitable \u201cloco-regional rescue therapy\u201d to further reduce tumor progression or even reach a curative effect. Studies of this treatment strategy in randomized clinical trials are warranted to further assess its safety and effectiveness.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000021344","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T23:05:45Z","timestamp":1595372745000},"page":"e21344","source":"Crossref","is-referenced-by-count":8,"title":["Concomitant fulvestrant with reirradiation for unresectable locoregional recurrent estrogen receptor positive (ER+) breast cancer"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8242-1081","authenticated-orcid":false,"given":"Jingxian","family":"Ding","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The Third Hospital of Nanchang"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghong","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Fourth Affiliated Hospital of Nanchang University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoliu","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Third Hospital of Nanchang"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Third Hospital of Nanchang"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbing","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Third Hospital of Nanchang"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yali","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Third Hospital of Nanchang, Nanchang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3322\/caac.21583","article-title":"Breast cancer statistics, 2019","volume":"69","author":"Desantis","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"R3-20230915","first-page":"19","article-title":"Current strategies for the management of locoregional breast cancer recurrence","volume":"33","author":"Wapnir","year":"2019","journal-title":"Oncology (Williston Park)"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"256","DOI":"10.5306\/wjco.v10.i7.256","article-title":"Reirradiation of recurrent breast cancer with proton beam therapy: a case report and literature review","volume":"10","author":"Lin","year":"2019","journal-title":"World J Clin Oncol"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.breast.2017.03.008","article-title":"Reirradiation for locally recurrent breast cancer","volume":"33","author":"Marta","year":"2017","journal-title":"Breast"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s00066-017-1241-7","article-title":"Reirradiation + hyperthermia for recurrent breast cancer en cuirasse","volume":"194","author":"Oldenborg","year":"2018","journal-title":"Strahlenther Onkol"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bbrc.2013.01.006","article-title":"Fulvestrant radiosensitizes human estrogen receptor-positive breast cancer cells","volume":"431","author":"Wang","year":"2013","journal-title":"Biochem Biophy Res Commun"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/cam4.2095","article-title":"Fulvestrant in the treatment of hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: a review","volume":"8","author":"Li","year":"2019","journal-title":"Cancer Med"},{"key":"R9-20230915","first-page":"D11093","article-title":"Fulvestrant for hormone-sensitive metastatic breast cancer","volume":"1","author":"Lee","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","article-title":"Fulvestrant 500\u200amg versus anastrozole 1\u200amg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","volume":"388","author":"Robertson","year":"2016","journal-title":"Lancet"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.breast.2018.03.011","article-title":"Incidence of isolated local breast cancer recurrence and contralateral breast cancer: a systematic review","volume":"39","author":"Spronk","year":"2018","journal-title":"Breast"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/1097-0142(19930801)72:3<774::AID-CNCR2820720323>3.0.CO;2-Y","article-title":"Wide local excision of recurrent breast cancer in the thoracic wall","volume":"72","author":"Dahlstrom","year":"1993","journal-title":"Cancer"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1200\/JCO.1983.1.6.400","article-title":"Local or regionally recurrent carcinoma of the breast: results of therapy in 121 patients","volume":"1","author":"Beck","year":"1983","journal-title":"J Clin Oncol"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3322\/caac.21498","article-title":"Local cancer recurrence: the realities, challenges, and opportunities for new therapies","volume":"68","author":"Mahvi","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1677\/erc.0.0100375","article-title":"Interactions between radiation and endocrine therapy in breast cancer","volume":"10","author":"Schmidberger","year":"2003","journal-title":"Endocr Relat Cancer"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJM199605233342102","article-title":"The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer","volume":"334","author":"Recht","year":"1996","journal-title":"N Engl J Med"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ctrv.2018.06.015","article-title":"Optimal sequence of adjuvant endocrine and radiation therapy in early-stage breast cancer \u2013 a systematic review","volume":"69","author":"Mcgee","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2004.03.005","article-title":"Role of cell cycle in mediating sensitivity to radiotherapy","volume":"59","author":"Pawlik","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.2147\/OTT.S170736","article-title":"Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series","volume":"11","author":"Rusz","year":"2018","journal-title":"Onco Targets Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:00:08Z","timestamp":1694826008000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021344"}},"subtitle":["A case report and narrative review"],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":19,"journal-issue":{"issue":"30","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000021344","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]}}}